Overview
ALLO market data
Price History
ALLO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.87 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.55 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -269,835.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.99 – $4.46 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $685.1M · P/B 1.05 · P/S 3,477.83.
Company News
Allogene Therapeutics Files Prospectus For $500M OfferingBenzinga · Aug 12, 2026, 9:00 PM
8-K filing — Allogene Therapeutics, Inc. (ALLO)SEC EDGAR · Aug 12, 2026, 8:12 PM
Allogene Therapeutics Q2 EPS $(0.13) Beats $(0.17) Estimate, Sales $4.640M Beat $2.222K EstimateBenzinga · Aug 12, 2026, 8:08 PM
Allogene Therapeutics' Cemacabtagene Ansegedleucel Receives FDA's Regenerative Medicine Advanced Therapy, Fast Track Designations To Treat B-Cell LymphomaBenzinga · Jul 29, 2026, 12:31 PM
Allogene Therapeutics Publishes Data From Phase 1 TRAVERSE Trial Of ALLO-316 In Advanced Or Metastatic Renal Cell Carcinoma; Trial Shows 31% Confirmed Response Rate With Recommended Phase 2 Regimen; Robust Expansion And Tumor Infiltration SeenBenzinga · Jul 15, 2026, 12:33 PM
Allogene Therapeutics' Dr. David Chang, M.D., Ph.D. To Transition From President and Chief Executive Officer, Effective On June 30, 2026; Co. Elects Zachary Roberts, M.D., Ph.D. As President And Chief Executive Officer, Effective July 1, 2026Benzinga · May 28, 2026, 9:28 PM